Three-month interim results from a study led by the National Vision Research Institute, Australian College of Optometry, found repeated low-level red-light (RLRL) therapy effective and safe in controlling myopia progression among multi-ethnic school-aged children.  

The findings suggest the therapy’s potential as a globally applicable solution for myopia control, authors noted.  

In the three-month interim analysis of this 12-month, multi-ethnic, randomised clinical trial, RLRL therapy demonstrated axial length (AL) shortening of 0.06mm and a reversal of cycloplegic spherical equivalent (SE) (hyperopic shift) by 0.23D compared to baseline. In contrast, the single-vision spectacle group exhibited 0.02mm AL elongation and −0.04D SE change. 

No severe adverse events were reported in either of the groups. 

The study was published by Ophthalmic Epidemiology.